Company intelligence / Profile preview

Co-Diagnostics

Salt Lake City, Utah, United Statesco-dx.com ↗

Ownership: Public · CODX
Employees: ~100
Development stage: Commercial

Overview

Co-Diagnostics has developed a proprietary PCR diagnostic platform and oligonucleotide chemistry for rapid detection of infectious diseases. The company previously commercialized a COVID‑19 test kit under EUA/CE mark but recently withdrew its 510(k) FDA application for an enhanced version of its PCR Pro instrument/test to gather updated clinical data before resubmission. Clinical evaluations are planned in 2025 for new tests targeting tuberculosis, HPV multiplexing, and upper respiratory multiplexing

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic test (PCR-based)Oligonucleotide chemistry
Industry: Molecular Diagnostics

Financials

Market cap: $1.3M
Total revenue: $166.1K
Enterprise value: $-600.3K

Beyond the preview

Go deeper on Co-Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Co-Diagnostics.

Explore the full profile